Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM80GFL)

Drug Name
7,8,4'-trihydroxyisoflavone Drug Info
Synonyms
7,8,4'-Trihydroxyisoflavone; 8-Hydroxydaidzein; 75187-63-2; 4',7,8-Trihydroxyisoflavone; 7,8-Dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; 7,8-Dihydroxy-3-(4-hydroxy-phenyl)-chromen-4-one; 7,8-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; NSC678112; CHEMBL242739; NSC 678112; 4H-1-Benzopyran-4-one, 7,8-dihydroxy-3-(4-hydroxyphenyl)-; 7,4'-Trihydroxyisoflavone; AC1NV1M1; SCHEMBL571127; 7,8,4''-trihydroxyisoflavone; 4'',7,8-trihydroxyisoflavone; CTK5E1244; DTXSID20226169; MolPort-000-165-583; BMZFZTMWBCFKSS-UHFFFAOYSA-N
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5466139
CAS Number
CAS 75187-63-2
TTD Drug ID
DM80GFL
INTEDE Drug ID
DR2148

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosinase (TYR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [4]
Monobenzone DMVJS2K Vitiligo ED63.0 Approved [4]
Multi-epitope peptide melanoma vaccine DMZPEHY Melanoma 2C30 Phase 3 [5]
Melanoma vaccine DMQEC6Z Melanoma 2C30 Phase 3 [6]
Polynoma-1 DM3QDA6 Melanoma 2C30 Phase 2 [7]
MKC-1106-MT DMXKOW6 Melanoma 2C30 Phase 2 [8]
Multi-epitope tyrosinase/gp100 vaccine DMN68ZL Melanoma 2C30 Phase 2 [9]
PMID29130358-Compound-Figure11(3) DMSME2B N. A. N. A. Patented [10]
Benzothiazole analog 1 DMHXFCQ Albinism EC23.2 Patented [11]
Monoamine derivative 2 DMAZ6DI Albinism EC23.2 Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Amylosucrase (AMS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeic acid phenethyl ester DMRJKIV Discovery agent N.A. Investigative [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Amylosucrase (AMS) Main DME DEEZYQV Q1J0W0_DEIGD Substrate [2] , [3]

References

1 Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4.
2 Potential industrial production of a well-soluble, alkaline-stable, and anti-inflammatory isoflavone glucoside from 8-hydroxydaidzein glucosylated by recombinant amylosucrase of Deinococcus geothermalis. Molecules. 2019 Jun 15;24(12). pii: E2236.
3 The complete genome and proteome of Laribacter hongkongensis reveal potential mechanisms for adaptations to different temperatures and habitats. PLoS Genet. 2009 Mar;5(3):e1000416.
4 Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
5 Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
6 National Cancer Institute Drug Dictionary (drug id 685201).
7 An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
10 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
11 Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.